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Plasmacytoid dendritic cell (pDC) development has been linked to that of conventional dendritic cells via a
common dendritic cell precursor (CDP). In this issue of Immunity, Onai et al. (2013) outline a parallel but
more effective pathway to pDCs that proceeds via a novel CDP-like precursor.We humans tend to believe that our
heritage matters and that our ancestors
provide clues to our identity. Cellular
immunologists tend to do the same, but
at the level of cells as the unit of life.
Immunologists have long considered
interferon-producing plasmacytoid den-
dritic cells (pDCs) as part of the dendritic
cell (DC) family, even though in their
morphological appearance, migratory
behavior, and antigen-presenting prop-
erties they seem similar to members of
the B lymphocyte lineage. One strong
reason for classifying them as DCs is
that their development in mouse bone
marrow is linked to that of conventional
DCs (cDCs) via common intermediate
precursors and via a common depen-
dence on the cytokine Flt3 ligand.
Both lymphoid-restricted and myeloid-
restricted precursors retain a potential to
form DCs, including pDCs, and we have
argued that both lymphoid and myeloid
routes contribute to normal pDC de-
velopment (Sathe et al., 2013). However,
most recent commentaries have empha-
sized the myeloid route, because of the
discovery of the myeloid-derived com-
mon dendritic cell precursor (CDP) or
pro-DC precursor population that was
shown to be restricted to the production
of cDCs and pDCs (Onai et al., 2007;
Naik et al., 2007). CDPs are normally iso-
lated from bone marrow as lineage-nega-
tive cells expressing Flt3, moderate
amounts of c-kit, and relatively high
amounts of the receptor (R) for the
‘‘myeloid’’ cytokine M-CSF (otherwise
known as CSF-1). Onai et al. (2013) now
show that a major source of pDCs had
been missed. They describe a distinct
DC-restricted precursor that produces
predominantly pDCs, representing a
parallel stream of DC development
branching off from the myeloid pathway
(Figure 1).One reason for seeking additional sour-
ces of pDCs is the relative paucity of pDC
production, compared to cDC produc-
tion, from conventional CDPs. This has
been one reason for considering an addi-
tional lymphoid route to pDCs. Onai et al.
(2013) have now found an additional
source of pDCs down a myeloid route
from a precursor closely resembling the
well-established CDP, but differing in
lacking expression of the M-CSFR. The
developmental potential of this precursor
was assessed by culture with Flt3 ligand
as well as by transfer into irradiated recip-
ient mice. It is notable that like the
conventional M-CSFR+ CDP, this new
M-CSFR precursor population produces
both cDCs and pDCs; however, the bias is
strongly toward pDC production. The au-
thors consider the possibility that their
distinct population represents a pDC-
alone precursor contaminated with a little
of a cDC-precursor population, but there
is as yet no evidence for this. Originally
there seemed no logical reason why
a precursor lacking the receptor for
M-CSF should favor pDC production,
because M-CSF had been shown to pro-
mote pDC production almost as effec-
tively as Flt3 ligand (Fancke et al., 2008).
However, some have noted that the
setting of the sorting gate for M-CSFR
expression when isolating CDPs did
affect the yield of pDCs, and this may
have been the clue leading to the present
findings.
What then is the relationship between
the conventional M-CSFR+ CDP and this
distinct M-CSFR DC precursor? Onai
et al. (2013) propose that the former might
produce the latter by downregulation of
the M-CSFR. This downregulation might
have been induced by M-CSF itself, so
these precursors may have already had
a pDC-inducing signal from this cytokine.
Despite some evidence for this sequenceImmunityin the paper, the exact developmental
relationship between these two DC
precursors in bone marrow still needs
clarification. Onai et al. (2013) also note
that the distinct precursor can be pro-
duced within one division from the up-
stream lymphocyte-primed multipotent
precursor (LMPP) population, so there
could be a direct route to production of
this M-CSFR DC precursor bypassing
the conventional CDP. This derivation
from LMPPs is of particular interest
because in a recent study using ‘‘barcod-
ing’’ of LMPP cells, a remarkable extent of
precommitment to DC production was
found at this early stage of development
(Naik et al., 2013). It is possible that
some cells commit to pDC production at
a very early stage whereas others need
sustained exposure to Flt3 ligand and
other factors and accordingly commit to
pDC production downstream of this
distinct precursor stage.
For immunologists involved in the
detailed mapping of DC development,
this two-precursor, two-pathway model
offers some insights into previously puz-
zling findings. It has always been surpris-
ing that even some pDCs derived from the
common myeloid precursor (CMP) popu-
lation upstream of the CDP nevertheless
expressed some characteristic markers
of the lymphoid lineage, namely a history
of expression of RAG-1 and permanent
D-J rearrangements in their IgH genes
(Shigematsu et al., 2004). Such rearrange-
ments are not essential to pDC function
and have been considered as an acci-
dental consequence of initiating some
lymphoid-related gene expression pro-
grams during pDC development. The
expression of RAG-1, a prerequirement
for Ig gene rearrangement, has been
tracked back to a subset of precursors
within the CMP population (Sathe et al.,
2013). Onai et al. (2013) now find that38, May 23, 2013 ª2013 Elsevier Inc. 845
Figure 1. Revised Pathway of Plasmacytoid DC Development
Previous findings indicated that the common dendritic precursor (CDP), a myeloid lineage precursor ex-
pressing the M-CSF receptor, produced both cDCs and pDCs. Onai et al. (2013) now show that there are
two DC-restricted precursors, the previous CDP expressing the M-CSF receptor and producing predom-
inantly conventional DCs and an additional precursor lacking theM-CSF receptor and producing predom-
inantly pDCs. It is not yet clear whether this additional pDC-biased precursor is always derived from the
previous CDP population by downregulation of the M-CSF receptor, or whether it can be independently
generated. Although the extra detail in the revised model is important, the simpler earlier model may still
be used if the CDP definition is extended to include precursors lacking the M-CSF receptor as well as
those expressing it.
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Previewsthe myeloid-derived pDCs with these
‘‘lymphoid’’ characteristics are products
of this pDC precursor lacking expression
of the M-CSFR. The probability of
acquiring D-J Ig gene rearrangements is
apparently higher along this pathway to
pDCs.
What then determines whether cells
within these different pathways become
pDCs or cDCs or other hematopoietic
cell types? Onai et al. (2013) offer some
suggestions involving successive signals846 Immunity 38, May 23, 2013 ª2013 Elsevifrom Flt3 ligand, M-CSF, and thrombo-
poietin. The extent to which commitment
to pDCs is dictated by such signals from
cytokines versus stochastic events is not
yet clear. One unifying feature of pDC
development by all routes is the expres-
sion of and dependence on the transcrip-
tion factor E2-2 (Cisse et al., 2008). This
suggests that once commitment is initi-
ated at any stage of development, the
pDC transcription machinery overrides
any bias to other outcomes implied byer Inc.the expression of lineage-specific surface
markers.
For those many immunologists not in
the DC development field, all this may
represent ‘‘too much information.’’ For
themOnai et al. (2013) do offer an alterna-
tive viewpoint: simply expand the def-
inition of CDPs to include both the
M-CSFR+ and the new M-CSFR DC-
restricted precursors. CDP then becomes
a heterogeneous DC precursor popula-
tion giving a continuum of cDC-to-pDC
output. As with human ancestry, too
much detail on family history can be
confusing!REFERENCES
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